For over 20 years, T2-weighted MR sequences have been used to detect signal in long T2 components of tissue. Tissues, however, also contain short T2 components, which until recently were not detectable on MR. New sequences such as magic angle imaging and ultrashort TE have for the first time detected signal from tendons, ligaments, menisci, periosteum, and cortical bone, according to Prof. Graeme Bydder, a radiologist formerly at Hammersmith Hospital in London and now at the University of California, San Diego.
For over 20 years, T2-weighted MR sequences have been used to detect signal in long T2 components of tissue. Tissues, however, also contain short T2 components, which until recently were not detectable on MR. New sequences such as magic angle imaging and ultrashort TE have for the first time detected signal from tendons, ligaments, menisci, periosteum, and cortical bone, according to Prof. Graeme Bydder, a radiologist formerly at Hammersmith Hospital in London and now at the University of California, San Diego.
"In addition, ultrashort TE can directly detect signals from very tightly bound water in other tissues, which previously could only be observed indirectly using magnetization transfer," Bydder said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.